Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies
Liver International · 2025-07 · 45 (7)
DOI: 10.1111/liv.70166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 16.06.2025. Verfasst von Louis Petitjean und 6 weiteren Autor:innen. Beteiligte Einrichtung: PharmaNest Inc., Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PharmaNest Inc..
Abstract (Originalsprache)
Background and Aims Liver biopsy is the gold standard for assessing fibrosis in cirrhotic livers, yet cirrhosis is spatially heterogeneous and continuously remodels. This study evaluates a novel phenotypic digital pathology platform for continuous fibrosis severity quantification and sensitivity to sampling variability. Approach and Results Five needle biopsies were collected from 20 HCV‐cirrhotic livers during transplantation. Histological staging used the Laennec (4A–4C) and Beijing (progressive, regressive, indeterminate) systems. Collagen proportionate area (CPA) was measured via computerised morphometry. The FibroNest platform analysed high‐resolution, single‐fibre images to extract 336 parameters, generating a continuous fibrosis severity score (Ph‐FCS) and tailored scores for Laennec (Ph‐FCS(L)) and Beijing (Ph‐FCS(B)) systems. A comparative MASLD cohort ( n = 73, NASH‐CRN stages) was also included. The range of the Ph‐FCS was broader to cover the cirrhosis spectrum (6.44 units) than from F0 to F3 (5.39 units). Ph‐FCS was less affected by biopsy variability (16.7% ± 1.3%) compared to CPA (47.3% ± 4.5%). Ph‐FCS(L) and Ph‐FCS(B) demonstrated moderate concordance with the Laennec and Beijing stages. Their ability to classify patients into Laennec and Beijing stages was limited (0.610 < AUROCS < 0.789). At best, Ph‐FCS(L) and Ph‐FCS(B) distinguished stages 4A from 4C and P from R with AUROCs of 0.747(95% CI: 0.611–0.879) and 0.798 (95% CI: 0.645–0.929). Conclusions Phenotypic digital pathology biomarkers provide robust, continuous measures of fibrosis severity and activity. They enhance traditional staging systems by offering improved resolution and reduced sensitivity to biopsy variability, with potential value in cirrhosis sub‐staging and clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PharmaNest Inc., Princeton, New Jersey, USA.
- Department of Pathology, NYU Grossman Long Island School of Medicine, Long Island, New York, USA.
- Division of Liver Diseases, Department of Medicine, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University, Richmond, Virginia, USA.
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Mathieu Petitjean, Arun J Sanyal
Förderung
- PharmaNest Inc.
Zitieren
APA
Petitjean, L., Chen, L., Zhang, X., Schiano, T., Petitjean, M., Sanyal, A. J., & Fiel, M. (2025). Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies. Liver International, 45(7). https://doi.org/10.1111/liv.70166
Vancouver
Petitjean L, Chen L, Zhang X, Schiano T, Petitjean M, Sanyal AJ, et al. Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies. Liver International. 2025;45(7). doi:10.1111/liv.70166
BibTeX
@article{Petitjean2025,
author = {Petitjean, Louis and Chen, Li and Zhang, Xiaofei and Schiano, Thomas and Petitjean, Mathieu and Sanyal, Arun J and Fiel, MariaIsabel},
title = {Digital Pathology Quantification of the Continuum of Cirrhosis Severity in Human Liver Biopsies},
journal = {Liver International},
year = {2025},
volume = {45},
number = {7},
doi = {10.1111/liv.70166}
}
EUVIMED